LMP-744 clinical trials
Also written LMP744.
How each study uses LMP-744 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the LMP-744 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2017 (1)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 3
National Cancer Institute (NCI) (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1) · Mayo Clinic (1)
Often tested with
Tested in the same studies.
Dasatinib (1) · Fisetin (1) · Quercetin (1) · Temozolomide (1) · Single Agent Therapy (1)
Studies
Open first, then newest update. How each study uses LMP-744 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent GlioblastomaRecruitingPhase 1/2National Institute of Neurological Disorders and Stroke (NINDS)NCT07416188Written as LMP744
- Medication Combinations of Dasatinib, Quercetin, Fisetin, Temozolomide, LMP744, and Autologous TLPO Vaccine for the Treatment of Previously Treated Glioma With Residual DiseaseRecruitingEarly Phase 1Mayo ClinicNCT07025226Written as Topoisomerase-1 Inhibitor LMP744
- Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and LymphomasCompletedPhase 1National Cancer Institute (NCI)NCT03030417Written as LMP744
Codes
What other systems call LMP-744 · ClinicalTrials.gg INT014441
- UNII (FDA) 29BY7HQV0TLMP-744Confirmed FDA, Wikidata
- Wikidata Q27894415lmp-744Confirmed FDA, Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 29BY7HQV0T | LMP-744 | Confirmed FDA, Wikidata |
| Wikidata | Q27894415 | lmp-744 | Confirmed FDA, Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.